TGFBR1 and glioblastoma: Another two studies use the TβRI inhibitor, LY2157299 (galunisertib): one combines it with lomustine to treat recurrent GBM (NCT01582269, active but not recruiting), and the other combines it with radiation and temozolomide in patients with newly diagnosed malignant glioma.